Cancer Research UK

Cancer Grand Challenges: Embarking on a new era of discovery

View this email in your browser

Dear Voornaam,

Its an exciting time for Cancer Grand Challenges having just announced 11 teams shortlisted to compete for our next round of funding. We were delighted to receive bold, innovative ideas from nearly 170 teams, representing 1,962 investigators across 61 countries. Congratulations and good luck to the 11 teams!

Our current teams also continue to make strides towards tackling some of cancer's toughest challenges. This includes identifying the molecule Notum as a key player in the very early stages of colorectal cancer and learning more about aspirins potential in personalised cancer prevention. Discover more below.

Best wishes,

The Cancer Grand Challenges team

The 2021 Cancer Grand Challenges shortlist

Were pleased to reveal 11 teams with the opportunity to receive up to 20m each in our next round of funding. Discover how these teams, spanning 82 institutions and 18 countries, are proposing to tackle each challenge.

View the teams

Revealing the early stages of APC-driven colorectal cancer

In Nature, SPECIFICANCER uncover what causes Apc-mutant cells to drive the very early stages of colorectal cancer and identify the molecule Notum as a key player.

The microbiome and aspirin's potential in personalised prevention

Caitlin Brennan of OPTIMISTICC discusses aspirins antibacterial activity against Fusobacterium nucleatum, a microbe associated with colorectal cancer.

In conversation with Owen Sansom and Helen Matthews

Members of the SPECIFICANCER team meet to discuss their latest findings and the important perspectives brought to the programme by patient advocacy.

Involving people affected by cancer in research

Watch advocacy panel chair Margaret Grayson, share the role the advocate voice plays in shaping our challenges and research.

Watch

Jelle Wesseling

We sat down with lead of our PRECISION team, Jelle Wesseling, to discuss his motivations, the teams aims to distinguish between harmless and hazardous DCIS, and the importance of looking beyond our own backyards.

Discover more

You are playing a crucial role in helping us beat cancer sooner, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.

Your details are safe with us. Check out our Privacy Policy.

Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.

This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ.